All the news Showing 10 of 20 articles from: AASLD 2014Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Ns5A inhibitors Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients Liz Highleyman / 02 December 2014 A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to phase 2 study ... Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection Liz Highleyman / 14 November 2014 An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates for treatment-naive and treatment-experienced people with genotype 1 hepatitis C ... Genotype 4 Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4 Liz Highleyman / 13 November 2014 [Editor's Note: this article previously stated that the PEARL-I trial tested the AbbVie 3D Viekira Pak regimen for HCV genotype 4. In actuality, the study used the 2D regimen consisting of the paritaprevir coformulation without dasabuvir. The article has been corrected.] Sofosbuvir/ledipasvir without ribavirin and ... Cirrhosis Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis Liz Highleyman / 12 November 2014 An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation ... Liver transplants People living with HIV have high survival rates after liver transplants due to HCC Keith Alcorn / 12 November 2014 People with HIV – most of whom had hepatitis B or C co-infection – generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with five-year survival rates similar to those ... Testing for hepatitis B Hepatitis B testing and treatment rates are low among US veterans Liz Highleyman / 11 November 2014 Only 15% of US veterans have been tested for hepatitis B virus (HBV) infection, and among those who tested positive just one-quarter received antiviral treatment and 13% were screened for liver cancer ... Drug dependence treatment Young drug injectors on opioid maintenance therapy have lower risk of hepatitis C infection Liz Highleyman / 11 November 2014 Young people who inject drugs (PWID) who undergo opioid agonist maintenance therapy with methadone or buprenorphine have more than a 60% reduced risk of acquiring hepatitis C virus (HCV) over time compared to ... Interferon-free regimens Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis Liz Highleyman / 11 November 2014 A 12-week all-oral regimen of daclatasvir, asunaprevir and beclabuvir, with or without ribavirin, cured 86 to 90% of genotype 1 hepatitis C patients with cirrhosis in the phase 3 UNITY-2 trial, while the ... Treatment outcomes Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants Liz Highleyman / 10 November 2014 People who achieve sustained virological response (SVR) when treated with interferon-based therapy for hepatitis C have a lower risk of death, are less likely to develop liver cancer and need fewer liver transplants ... Treatment for people living with HIV and HCV Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection Liz Highleyman / 10 November 2014 All but one participant treated for hepatitis C virus (HCV) with a co-formulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment, in a study involving people with ... ← Prev12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive